Comparative Safety of Ibrutinib Versus Zanubrutinib in Patients With Chronic Lymphocytic Leukemia: A Prospective Cohort Study
Hematological Oncology · 2025
DOI: 10.1002/hon.70041 ↗At a glance
Vergleichsstudie in Hematological Oncology, 2025. Written by Fuli Fan and 7 co-authors. Institution: Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China. Major MEDLINE topics: Leukemia, Lymphocytic, Chronic, B-Cell, Piperidines, Pyrimidines, Pyrazoles. 23 references. Funded by: National Nature Science Foundation of Shandong Province.
Abstract (original language)
This study compares the safety profiles of two Bruton's tyrosine kinase (BTK) inhibitors, Ibrutinib and Zanubrutinib, in patients with chronic lymphocytic leukemia (CLL). While Ibrutinib has transformed CLL treatment, it is associated with significant adverse events (AEs). Zanubrutinib, a second‐generation BTK inhibitor, offers potential for improved safety. In this prospective study, 200 CLL patients were enrolled, with 100 receiving Ibrutinib and 100 receiving Zanubrutinib. Baseline characteristics such as age, sex, body mass index (BMI), Eastern Cooperative Oncology Group (ECOG) performance status, and genetic factors were evaluated. AEs and serious AEs (SAEs) were tracked and graded using the Common Terminology Criteria for Adverse Events (CTCAE). Multivariate logistic regression models were conducted to determine predictors of SAE and AEs grade ≥ 3. Adjusted odds ratio (aOR) and 95% confidence interval (CI) were reported. The mean ages of the Ibrutinib and Zanubrutinib groups were 49.65 and 49.16 years, respectively ( p = 0.285). The Zanubrutinib group had a higher percentage of patients with worse ECOG status (71% vs. 57%, p = 0.039). Fewer Zanubrutinib patients experienced severe AEs (4% vs. 9%, p = 0.152) or SAEs (8% vs. 17%, p = 0.054). Neutropenia occurred only in the Ibrutinib group (3%). Subgroup analysis showed a higher complication rate with Zanubrutinib in non‐refractory patients (11.40% vs. 5.26%, p = 0.065). Stage III CLL was a protective factor of grade ≥ 3 AEs (aOR = 0.007; 95% CI: 0.0003–0.1829) and SAE (aOR = 0.015; 95% CI: 0.001–0.177). While ECOS status (2 vs. 3) resulted in reduced risk of SAE, chromosome 17p deletion emerged as the main risk factor of SAE (aOR = 6.40; 95% CI: 1.33–30.79). Zanubrutinib demonstrated a more favorable safety profile than Ibrutinib, with fewer severe adverse events. It may be a safer alternative for CLL patients, particularly those at higher risk for complications from BTK inhibitors. However, these differences stemmed from variability in baseline clinical characteristics rather than the interventions themselves.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.
- Department of Critical Care Medicine, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.
ORCID profiles: Yuting Yan
Funding
- National Nature Science Foundation of Shandong Province
Cite
APA
Fan, F., Liu, X., Su, Z., Li, S., Wang, C., Wang, S., Cui, S., & Yan, Y. (2025). Comparative Safety of Ibrutinib Versus Zanubrutinib in Patients With Chronic Lymphocytic Leukemia: A Prospective Cohort Study. Hematological Oncology. https://doi.org/10.1002/hon.70041
Vancouver
Fan F, Liu X, Su Z, Li S, Wang C, Wang S, et al. Comparative Safety of Ibrutinib Versus Zanubrutinib in Patients With Chronic Lymphocytic Leukemia: A Prospective Cohort Study. Hematological Oncology. 2025. doi:10.1002/hon.70041
BibTeX
@article{Fan2025,
author = {Fan, Fuli and Liu, Xiaodan and Su, Zhan and Li, Saisai and Wang, Chuanlei and Wang, Shibo and Cui, Shuxia and Yan, Yuting},
title = {Comparative Safety of Ibrutinib Versus Zanubrutinib in Patients With Chronic Lymphocytic Leukemia: A Prospective Cohort Study},
journal = {Hematological Oncology},
year = {2025},
doi = {10.1002/hon.70041}
}
EUVIMED